Phenylalanine – Quantitative Plasma Test

The Phenylalanine – Quantitative Plasma Test accurately measures the concentration of phenylalanine in a plasma sample. Phenylalanine is an essential amino acid obtained through protein-containing foods. The body normally uses phenylalanine for growth, protein production and the formation of other biologically important substances.

In healthy metabolism, an enzyme called phenylalanine hydroxylase converts phenylalanine into tyrosine. Reduced activity of this enzyme can cause phenylalanine to accumulate in the blood. The best-known condition associated with this abnormality is phenylketonuria, commonly abbreviated as PKU.

Quantitative plasma testing differs from routine neonatal screening. A newborn dried blood spot is designed to identify babies who may be at increased risk, whereas quantitative plasma analysis provides a more precise concentration for diagnostic evaluation and clinical management. It may be requested after an out-of-range newborn screen or for continued monitoring of a patient with confirmed PKU or another form of hyperphenylalaninaemia.

Persistently elevated phenylalanine can be toxic to the developing brain. Without appropriate treatment, severe elevations may affect intellectual development, behaviour, attention, movement and neurological function. Accurate measurement helps the specialist diagnose the underlying condition, assess its severity and develop an individual treatment plan.

Benefits of Quantitative Plasma Phenylalanine Testing

• Provides a quantitative measurement of phenylalanine in plasma.
• Supports confirmation of an abnormal newborn screening result.
• Helps diagnose phenylketonuria and other causes of hyperphenylalaninaemia.
• Supports classification of phenylalanine hydroxylase deficiency.
• Helps distinguish transient elevation from persistent metabolic disease.
• Guides dietary and medical treatment decisions in confirmed PKU.
• Monitors response to a prescribed low-phenylalanine diet.
• Supports evaluation before and during pharmacological treatment.
• Helps monitor phenylalanine during pregnancy in women with PKU.
• Provides objective information for long-term metabolic follow-up.

Understanding Phenylalanine Metabolism

Phenylalanine is one of the amino acids used to produce proteins. Because the body cannot make sufficient phenylalanine independently, it must be obtained from the diet. It is naturally present in breast milk, infant formula, dairy products, eggs, meat, fish, pulses, nuts and many other protein-containing foods. Aspartame, an artificial sweetener, also contains phenylalanine.

Phenylalanine hydroxylase normally converts phenylalanine into tyrosine. This reaction requires tetrahydrobiopterin, also called BH4, as a cofactor. Tyrosine contributes to the production of proteins, thyroid hormones, melanin and several neurotransmitters.

Classical PKU most often results from disease-causing variants in the PAH gene. These variants reduce or eliminate phenylalanine hydroxylase activity. PKU usually follows an autosomal recessive inheritance pattern, meaning that an affected person has generally inherited one altered gene copy from each biological parent.

When both parents carry a disease-causing variant in the PAH gene, each pregnancy generally has a 25% probability of an affected child, a 50% probability of a carrier child and a 25% probability of a child who inherited neither familial variant. A genetic counsellor can interpret the risk for a specific family.

Not all elevations are caused by classical PKU. Milder PAH deficiency, tetrahydrobiopterin synthesis or recycling disorders, liver dysfunction, serious illness, prematurity and nutritional factors may also increase phenylalanine. Appropriate follow-up testing is needed to establish the cause.

What Does the Test Measure?

The test measures the concentration of phenylalanine in plasma, generally reported in micromoles per litre or milligrams per decilitre. The result may be included in a quantitative plasma amino acid profile or reported as an individual analyte, depending on the laboratory method and clinical request.

Many laboratories use high-performance liquid chromatography, liquid chromatography–mass spectrometry, tandem mass spectrometry or another validated quantitative method. These analytical techniques separate and measure amino acids with greater specificity than an initial screening procedure.

The reference interval depends on the patient's age, clinical condition, analytical method and laboratory. A diagnostic threshold or treatment target should not be assumed from a general reference range. Newborn screening cut-offs, diagnostic plasma concentrations and treatment-monitoring targets serve different purposes.

The phenylalanine-to-tyrosine ratio may provide additional information. An elevated ratio can support the biochemical assessment of impaired phenylalanine conversion, but it cannot independently identify the precise genetic or enzymatic cause.

Clinical Indications and Applications

Confirmation After Newborn Screening: Quantitative plasma phenylalanine is commonly requested when a newborn dried blood spot shows an increased or borderline phenylalanine result. Confirmatory testing should be completed promptly because early treatment is important when PKU is present.

Diagnosis of Hyperphenylalaninaemia: Persistent elevation requires evaluation for classical PKU, mild PAH deficiency, BH4-related disorders and secondary causes. Serial measurements may help determine whether the elevation is transient or persistent.

Monitoring Confirmed PKU: Patients with PKU require regular phenylalanine measurements throughout life. Monitoring helps the metabolic team adjust medical nutrition, natural protein intake, specialised formula and prescribed treatment.

Assessment of Treatment Response: The test may be used to evaluate response to a low-phenylalanine diet, sapropterin or other specialist-prescribed treatments. The frequency of testing depends on age, clinical stability, treatment type and metabolic control.

Maternal PKU Monitoring: Women with PKU require careful metabolic management before conception and throughout pregnancy. Excessive maternal phenylalanine can affect fetal development even when the fetus does not have PKU.

Neurological or Developmental Evaluation: Quantitative analysis may be considered when unexplained developmental delay, intellectual impairment, seizures, behavioural changes or neurological abnormalities raise concern about an undiagnosed amino acid metabolism disorder.

Why Doctors Recommend This Test

A screening result can identify increased risk but cannot provide a final diagnosis. Quantitative plasma analysis determines the actual concentration and supports decisions about the urgency of treatment and the need for further metabolic investigation.

For patients with established PKU, treatment must maintain phenylalanine within an individual target while providing adequate nutrients for growth and health. Too much phenylalanine can be harmful, but excessive restriction can cause nutritional deficiency. Regular testing helps the clinical team maintain the appropriate balance.

Phenylalanine concentrations can change with dietary intake, illness, fever, growth, pregnancy, fasting, poor appetite and treatment adherence. A previously stable patient may therefore require additional monitoring during major clinical or nutritional changes.

The result should be reviewed by a paediatric metabolic physician, neurologist, clinical geneticist or another appropriately qualified clinician. Parents and patients should not independently change dietary protein or medical formula based on a single result.

Preparation Before the Test

Preparation depends on the clinical purpose and laboratory protocol. Fasting may not always be required, particularly when urgent confirmation is needed in a newborn. However, some laboratories or clinicians may request collection under standardised fasting or pre-feed conditions to improve comparability between measurements.

Follow the instructions provided by the treating doctor or laboratory. Do not withhold breast milk, infant formula, medical formula, natural protein, supplements or prescribed medicines unless specifically instructed by the metabolic specialist.

Inform the laboratory about the patient's age, feeding status, time of the last meal or feed, prescribed medical formula, current treatment and reason for testing. For newborns, provide the date and time of birth, gestational age, birth weight, newborn screening result and any use of parenteral nutrition.

Also report prematurity, liver disease, recent infection, fever, vomiting, prolonged fasting, poor nutritional intake, pregnancy or a known diagnosis of PKU. These factors may influence the concentration or clinical interpretation.

Plasma Sample Collection Procedure

A trained phlebotomist collects blood from a vein, usually in the arm for older children and adults. In infants, an appropriate peripheral vein is selected by a healthcare professional experienced in paediatric collection. The blood is collected in the tube specified by the laboratory.

The sample must be handled promptly because delayed separation or unsuitable storage can affect amino acid measurements. Plasma is separated from the blood cells and stored or transported according to the validated laboratory protocol.

The procedure generally takes a few minutes. Temporary discomfort, mild bruising or light-headedness may occur. Significant complications are uncommon. An insufficient, haemolysed, contaminated, incorrectly labelled or improperly transported specimen may need to be recollected.

Laboratory Analysis and Reporting

The laboratory analyses the plasma using chromatography, mass spectrometry or another validated quantitative amino acid method. The report includes the measured phenylalanine concentration, unit and relevant reference interval. It may also include tyrosine, a phenylalanine-to-tyrosine ratio or other amino acids.

If the concentration is elevated, follow-up testing may include a complete plasma amino acid profile, urine organic acids, urine or blood pterins, dihydropteridine reductase activity and molecular genetic testing. These investigations help distinguish PAH-related PKU from BH4 synthesis or recycling disorders.

Genetic analysis can confirm disease-causing variants, support disease classification and enable family testing. Treatment should not be delayed in a newborn with a markedly elevated concentration while waiting for genetic results.

Serial results are often more informative than one isolated measurement. Follow-up samples should be collected under reasonably consistent conditions whenever possible so the metabolic team can evaluate trends accurately.

Normal Reporting Time

The report for the Phenylalanine – Quantitative Plasma Test is generally available within 3 to 5 working days after the laboratory receives an acceptable plasma sample. Actual reporting time may vary according to specimen transport, laboratory workflow, analytical method and whether testing is performed at a referral laboratory.

Urgent neonatal results may be communicated earlier according to laboratory policy. Additional biochemical investigations and molecular genetic testing require separate processing and reporting times.

Who Should Consider This Test?

• Newborns with an elevated or borderline phenylalanine screening result.
• Babies with a sibling or family member affected by PKU.
• Children whose parents are known carriers of PAH variants.
• Patients undergoing diagnostic evaluation for hyperphenylalaninaemia.
• Individuals with confirmed PKU requiring treatment monitoring.
• Patients receiving a prescribed low-phenylalanine diet or medical formula.
• Patients being assessed for response to specialist PKU medicines.
• Women with PKU planning pregnancy or currently pregnant.
• Patients with unexplained neurological or developmental findings.
• Individuals specifically referred by a metabolic specialist or clinical geneticist.

Understanding the Test Results

Phenylalanine Within the Reference Interval: An in-range result makes significant hyperphenylalaninaemia less likely at the time of collection. It does not always exclude a mild or intermittent abnormality, particularly when there is a strong family history or previous abnormal screening result.

Elevated Phenylalanine: An increased concentration may indicate classical PKU, mild PAH deficiency, a BH4-related disorder or a secondary cause. The degree of elevation, phenylalanine-to-tyrosine ratio, age, diet and previous results must be considered.

Persistently Elevated Results: Repeated elevation generally requires specialist evaluation and additional biochemical or genetic testing. Treatment requirements depend on the confirmed disorder and the patient's individual concentration.

Result During Treatment: For a patient with confirmed PKU, the result is compared with an age- and condition-specific treatment target rather than only with the general laboratory reference interval.

Clinical Limitations

A single plasma phenylalanine result cannot independently establish the underlying genetic disorder, predict long-term outcome or determine the complete treatment plan. Diagnosis requires correlation with screening history, quantitative amino acids, specialised biochemical tests and sometimes molecular analysis.

Food intake, fasting, illness, fever, growth, pregnancy, treatment adherence, specimen timing and sample handling can affect the concentration. Results from dried blood spots and plasma are not directly interchangeable, and different analytical methods may produce small differences.

Reference intervals and treatment targets are not the same. A concentration considered acceptable for an individual receiving treatment may differ according to age, pregnancy status, clinical guidelines and specialist recommendations.

Secondary hyperphenylalaninaemia can occur with severe liver dysfunction, critical illness or other metabolic disturbances. The result must therefore be interpreted within the patient's complete clinical context.

Important Safety Information

A markedly elevated phenylalanine result in a newborn requires urgent review by a paediatric metabolic specialist. Early treatment is important, but parents should not independently stop breast milk, formula or protein intake while awaiting advice.

Patients with confirmed PKU should not alter medical formula, natural protein intake, supplements or prescribed medicines without consulting their metabolic team. Both excessive phenylalanine exposure and overly restrictive nutrition can be harmful. This laboratory test supports clinical management but does not replace specialist assessment.